Skip to main content

Health & Wellness

Weight Regain After Stopping GLP-1 Medication

By Allura Health & WellnessPublished Updated 3 min read
Allura editorial illustration

For your understanding.

This article is for general education and is not medical advice. It does not replace an individual assessment or guidance from a qualified healthcare professional.

Weight regain after stopping GLP-1-based medication is common in clinical studies. Healthy eating, activity and follow-up remain important, but they cannot guarantee that lost weight will stay off after treatment ends. Regain is a reason to review care, not a personal failure.

If you are considering a change because of cost, side effects, pregnancy plans or another concern, involve the prescriber before changing treatment. A maintenance conversation should include the reason for stopping and the health condition the medicine is treating.

What the semaglutide withdrawal study found

The STEP 1 extension followed a subset of 327 participants for a year after the trial treatment period. In the semaglutide group, average weight loss during treatment was 17.3% of starting weight. After withdrawal, participants regained 11.6 percentage points, roughly two-thirds of the previous loss, leaving an average net loss of 5.6% from baseline.

The distinction between percentages matters: two-thirds of the weight previously lost is not two-thirds of total body weight. These were group averages, with substantial individual variation.

The extension was exploratory and included selected trial completers. Both medication and the structured lifestyle intervention ended, so the results do not isolate medication withdrawal from that change in support. Participants in the original trial did not have diabetes. The study does not predict exactly what will happen to one person or establish a tapering method.

What the tirzepatide withdrawal trial adds

In SURMOUNT-4, adults first received tirzepatide during a 36-week open-label period. The 670 participants who proceeded to randomization either continued treatment or switched to placebo for another 52 weeks, with lifestyle support continuing.

After an average initial loss of 20.9%, the placebo-switch group gained 14.0% relative to their weight at randomization. The continuing-treatment group lost a further 5.5% on that same time-point basis. Those numbers describe different phases and cannot simply be added as if they all use starting weight as the denominator.

The trial supports continued-treatment benefit in the studied population; it does not prove that every patient must stay on the same product indefinitely. Participants had completed the initial treatment period, and diabetes was excluded. Neither this study nor STEP 1 tested a universal transition plan for all patients.

Why the long-term plan matters

Obesity is a chronic condition, and the NIDDK notes that some people may need ongoing medication when treatment remains beneficial and appropriate. The decision should weigh health benefits, tolerability, access and preferences with the clinician.

A return of appetite or weight after stopping does not erase the effort made during treatment. It can indicate that the treatment effect is no longer present or that the care plan needs to change. Avoid a promise that a supplement, a strict diet or more discipline can reliably replace that effect.

Prepare for a possible treatment change

Questions to discuss include:

  • Why are we considering stopping, and what alternatives address that reason?
  • If I also have diabetes or another treated condition, what monitoring and treatment will continue?
  • When will follow-up occur, and what changes should lead to earlier contact?
  • How will appetite, intake, weight trend, strength and relevant health measures be reviewed?
  • What support is available if medication becomes unaffordable or unavailable?

A prescriber should direct stopping, restarting, switching or any other dosing decision. The withdrawal studies are evidence to discuss, not instructions to experiment with medication.

Keep habits supportive and expectations realistic

A workable food pattern, appropriate activity, sleep and attention to muscle and function remain useful parts of care. They support health whether or not weight changes and should fit medical needs and daily life.

The practical next step is a planned follow-up, not a guarantee of no regain. For an overview of care decisions, see what to expect from a medical weight loss consultation.

Your next step

Plan the conversation beyond the initial weight change.

Explore Allura’s medical weight-management service and ask the care team about discussing maintenance, follow-up and your current routine.

Keep medication changes with your prescribing clinician. A consultation or product purchase does not guarantee weight maintenance.